Effects of 8-OHdG, H-FABP and CRP on the Development of Ischemic Cardiomyopathy.

Qingquan WU; Yong ZHANG; Xiuxian HUANG

[Objectives] To analyze the relationship between serum 8-hydroxydeoxyguanosine (8-OHdG), heart fatty acid-binding protein (H-FABP), C-reactive protein (CRP) levels and clinical efficacy and short-term prognosis in patients with ischemic cardiomyopathy. [Methods] The clinical data of 100 patients with ischemic cardiomyopathy from October 2021 to November 2022 w'ere retrospectively analyzed, and the serum levels of 8-OHdG, H-FABP and CRP were compared before and one week after treatment. The patients were followed up for 12 months after discharge, and the incidence of major adverse cardiovascular events (MACE) was counted during the follow-up period. Univariate and multivariate Logistic regression analysis were used to analyze the prognostic factors of patients with ischemic cardiomyopathy in the near future, and the predictive value of serum 8-OHdG, H-FABP and CRP levels for the prognosis of patients was evaluated by ROC curve. [Results] After 1 week of treatment, the serum levels of 8-OHdG, H-FABP and CRP in patients with ischemic cardiomyopathy were significantly lower than those before treatment (P < 0.05). During the follow'-up period, 34 patients developed MACE; the serum levels of 8-OHdG, H-FABP and CRP in the MACE group were higher than those in the non-MACE group, and the differences were statistically significant (P < 0. 05). Multivariate Logistic regression analysis show'ed that 8-OHdG, H-FABP and CRP w'ere the risk factors of MACE in patients w'ith ischemic cardiomyopathy (P<0.05). ROC curve analysis showed that the combined prediction of 8-OHdG, H-FABP and CRP for MACE in patients with ischemic cardiomyopathy was higher than that of CRP, H-FABP and 8-OHdG alone (P <0.05). [Conclusions] 8-OHdG, H-FABP and CRP are closely related to the clinical efficacy and short-term prognosis of patients with ischemic cardiomyopathy, and the detection of serum 8-OHdG, H-FABP and CRP levels can help to evaluate the clinical efficacy and short-term prognosis of patients with ischemic cardiomyopathy.

FATTY acid-binding proteins; MAJOR adverse cardiovascular events; LOGISTIC regression analysis; CARRIER proteins; C-reactive protein

Medicinal Plant, 2024, Vol 15, Issue 4, p69

2152-3924

Academic Journal

10.19600/j.cnki.issn2152-3924.2024.04.014